Safety and effectiveness study of a new medication for children with Tourette syndrome

The purpose of this research study is to look at the safety and effectiveness of pramipexole in children with Tourette’s disorder. Approximately 62 children between the ages of 6 and 17 will take part in this research study; three to nine subjects will be enrolled at Rush University Medical Center. Participation in this study will last for about 10 weeks and will include about seven to eight visits.

You may be eligible to participate in this study if you:

• Are between 6-17 years of age
• Have the ability and willingness to comply with study treatment regimen and to attend study assessments
• Have been diagnosed with Tourette Disorder
• Are having at least 1 tick/day associated with evidence of social disabling functioning
• Are willing to submit a written informed consent provided by the patient’s parent (or legal guardian) and assent provided by the patient

You will be excluded from this study if you:

• Are a female of childbearing potential who is pregnant and/or nursing
• Are a female of childbearing potential not using a medically accepted method of contraceptive
• Have any other conditions or disorder which would exclude them from participation

This is a partial list of eligibility requirements. To inquire about your eligibility, please call the contact number provided. If you wish to inquire via e-mail, please include the title of the study in your message.